John Libbey Eurotext

VEGF Actu

Nouvelles stratégies anti-tumorales : ciblage sélectif des formes pro-angiogéniques de VEGF Volume 12, numéro 1, Mars 2017

  • [1] Escudier B, Bellmunt J, Negrier S. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28:2144-50.
  • [2] Pivot X, Schneeweiss A, Verma S. Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO. Eur J Cancer. 2011;47:2387-95.
  • [3] Catena R, Larzabal L, Larrayoz M. VEGF121b and VEGF165b are weakly angiogenic isoforms of VEGF-A. Mol Cancer. 2010;9:320.
  • [4] Nowak DG, Woolard J, Amin EM. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J Cell Sci. 2008;121:3487-95.
  • [5] Grepin R, Guyot M, Jacquin M. Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines. Oncogene. 2012;31:1683-94.
  • [6] Varey AH, Rennel ES, Qiu Y. VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. Br J Cancer. 2008;98:1366-79.
  • [7] Harper SJ, Bates DO. VEGF-A splicing: the key to antiangiogenic therapeutics? Nat Rev Cancer. 2008;8:880-7.
  • [8] Paez-ibes M, Allen E, Hudock J. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15:220-31.
  • [9] Ebos JM, Lee CR, Cruz-Munoz W. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15:232-9.
  • [10] Bates DO, Catalano PJ, Symonds KE. Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab. Clin Cancer Res. 2012;18:6384-91.
  • [11] Bukowski RM, Kabbinavar FF, Figlin RA. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol. 2007;25:4536-41.
  • [12] Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol. 2010;11:1172-83.